| Title | Frequency distribution of drug metabolizing enzymes CYP2A6 and NAT2 in 390 healthy Greek volunteers | |
| Authors | N. Drakoulis, K. Balaskonis, E. Malliara, E. Livadarou and S. Katsoula
School of Pharmacy, University of Athens, Greece |
|
| Citation | Drakoulis, N., Balaskonis, K., Malliara, E., Livadarou, E., Katsoula, S.: Frequency distribution of drug metabolizing enzymes CYP2A6 and NAT2 in 390 healthy Greek volunteers, Epitheorese Klin. Farmakol. Farmakokinet. 20(2): 153-154 (2006) | |
| Publication Date | Accepted for publication: 19-20 May 2006 | |
| Full Text Language | English | |
| Order – Buy | Ηλεκτρονική Μορφή: pdf (10 €) – Digital Type: pdf (10 €)
pharmakonpress[at]pharmakonpress[.]gr |
|
| Keywords | NAT2, CYP2A6, genetic polymorphism, phenotype, Greek population. | |
| Other Terms | review article | |
| Summary | The aim of this study was to assess the frequency of genetic polymorphisms of the hepatic metabolic enzymes CYP2A6 and NAT-2 in the Greek population. 390 healthy volunteers (171 men and 219 women, 19-83 years) were phenotyped using the in vivo Caffeine Test. The phenotyping revealed that only 4.87% of the Greek population had low CYP2A6 activity and that 47% of the population were slow metabolizers. No correlation was demonstrated between catalytic activity of both enzymes and gender or smoking habits. Age seems to influence the acetylator status, since the prevalence of slow acetylators among young people ≤30 years was 54% and among people >30 years the frequency was just 41%). | |
| References | 1. Chun Xu, Shari G., Edward M., Tyndale R.F.: CYP2A6 genetic variation and potential consequences. Adv. Drug Del. Rev. 54: 1245-1256 (2002)
2. Raunio H., Rautio A., Harriet G., Olavi P.: Polymorphisms of CYP2A6 and its practical consequences. Br. J. Clin. Pharmacol. 52: 357-363 (2001). 3. Cascorbi I., Drakoulis N., Brockmoller J., Maurer A., Sper- ling K., Roots I.: Arylamine NAT2 mutations and their allelic linkage in unrelated Caucasian individuals. Am. J. Hum. Genet. 57: 581-92 (1995) 4. Grant D.M., Tang B.K, Kalow W.: Variability in caffeine metabolism. Clin. Pharmacol. Ther. 33: 591-602 (1983) 5. Kalow W., Tang B.K.: Caffeine as a metabolic probe: Exploration of the enzyme-inducing effect of cigarette smoking. Clin. Pharmacol. Ther. 49: 44-49 (1991) 6. Welfare M.R., Bassendine M.F., Daly A.K.: The effect of NAT2 genotype and gender on the metabolism of caffeine in non-smoking subjects. Br. J. Clin. Pharmacol. 49: 240-243 (2000) 7. Drakoulis N., Malliara E., Balaskonis K., Haliassos E., Bauer S., Skarleas C., Kyprianou K.: Genetic Polymorphism and chemical carcinogenesis: assessment of the enzymes NAT2, CYP2A6 and CYP1A2 metabolizing activity among Greek lung cancer patients and controls. Basic Clin. Pharm. Toxicol. 97: (2005) |
|
| Relative Papers |
Online ISSN 1011-6575
Άρθρα Δημοσιευμένα σε αυτό το Περιοδικό Καταχωρούνται στα:
- Chemical Abstracts
- Elsevier’s Bibliographic Databases: Scopus, EMBASE, EMBiology, Elsevier BIOBASE SCImago Journal and Country Rank Factor
Articles published in this Journal are Indexed or Abstracted in: • Chemical Abstracts • Elsevier’s Bibliographic Databases: Scopus, EMBASE, EMBiology, Elsevier BIOBASE SCImago Journal and Country Rank Factor
Συντακτικη Επιτροπή-Editorial Board
| ΕΤΗΣΙΑ ΣΥΝΔΡΟΜΗ 2006 – ANNUAL SUBSCRIPTION 2006 | |
| Γλώσσα Πλήρους Κειμένου – Full Text Language | Αγγλικά – English |
| Παραγγελία – Αγορά – Order – Buy | Ηλεκτρονική Μορφή: pdf (70 €) – Digital Type: pdf (70 €)
pharmakonpress[at]pharmakonpress[.]gr |
| Έντυπη Μορφή (70 € + έξοδα αποστολής) – Printed Type (70 € + shipping)
pharmakonpress[at]pharmakonpress[.]gr |
|